Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria

Journal of Inherited Metabolic Disease

Volumn 35, Issue 6, 2012, Pages 975-981

  Leuret, Oriane ^a,i   Barth, Magalie ^b,i   Kuster, Alice ^c,i   Eyer, Didier ^d   De Parscau, Loïc ^e,i   Odent, Sylvie ^f,i   Gilbert Dussardier, Brigitte ^g,i   Feillet, François ^h   Labarthe, François ^a,i,j  

^a UNIVERSITÉ DE TOURS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ Réseau Maladies Métaboliques Hôpitaux Universitaires du Grand Ouest   (France)

^j Centre de Pediatrie Clocheville   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SAPROPTERIN; TETRAHYDROBIOPTERIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CLINICAL ARTICLE; DIET THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERPHENYLALANINEMIA; LONG TERM CARE; MALE; METABOLIC REGULATION; PATIENT COMPLIANCE; PHENYLKETONURIA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION;

AGE FACTORS; BIOPTERIN; CHILD, PRESCHOOL; FEMALE; FRANCE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84867750195     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9464-3     Document Type: Article

References (26)

1. Adamczyk P, Morawiec-Knysak A, Pludowski P, Banaszak B, Karpe J, Pluskiewicz W (2011) Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria. J Bone Miner Metab 29:236-244
2. Anastasoaie V, Kurzius L, Forbes P, Waisbren S (2008) Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol Genet Metab 95:17-20
3. Antshel KM (2010) ADHD, learning, and academic performance in phenylketonuria. Mol Genet Metab 99(Suppl 1):S52-S58
4. Belanger-Quintana A, Garcia MJ, Castro M, et al.(2005) Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol Genet Metab 86(Suppl 1):S61-S66
5. Blau N, Erlandsen H (2004) The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 82:101-111
6. Blau N, Belanger-Quintana A, Demirkol M, et al.(2009) Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab 96:158-163
7. Boveda MD, Couce ML, Castineiras DE, et al.(2007) The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatment. J Inherit Metab Dis 30:812
8. Brumm VL, Grant ML (2010) The role of intelligence in phenylketonuria: a review of research and management. Mol Genet Metab 99(Suppl 1):S18-S21
9. Brumm VL, Bilder D, Waisbren SE (2010) Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 99(Suppl 1):S59-S63
10. Burton BK, Bausell H, Katz R, Laduca H, Sullivan C (2010) Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol Genet Metab 101:110-114
11. Burton BK, Adams DJ, Grange DK, et al.(2011) Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J Pediatr 158:410-415
12. Christ SE, Huijbregts SC, de Sonneville LM, White DA (2010) Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab 99(Suppl 1):S22-S32
13. Haute Autorité de Santé (2010) Phénylcé tonurie: Protocole National de Diagnostic et de Soins. http://www.has-sante.fr
14. Enns GM, Koch R, Brumm V, Blakely E, Suter R, Jurecki E (2010) Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab 101:99-109
15. Feillet F, Chery C, Namour F, et al.(2008) Evaluation of neonatal BH4 loading test in neonates screened for hyperphenylalaninemia. Early Hum Dev 84:561-567
16. Feillet F, van Spronsen FJ, MacDonald A, et al.(2010) Challenges and pitfalls in the management of phenylketonuria. Pediatrics 126:333-341
17. Gassio R, Artuch R, Vilaseca MA, et al.(2005) Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. Dev Med Child Neurol 47:443-448
18. Hennermann JB, Buhrer C, Blau N, Vetter B, Monch E (2005) Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 86(Suppl 1):S86-S90
19. Karacic I, Meili D, Sarnavka V, et al.(2009) Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol Genet Metab 97:165-171
20. Lambruschini N, Perez-Duenas B, Vilaseca MA, et al.(2005) Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 86(Suppl 1):S54-S60
21. Modan-Moses D, Vered I, Schwartz G, et al.(2007) Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 30:202-208
22. Muntau AC, Gersting SW (2010) Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism. J Inherit Metab Dis 33:649-658
23. Roato I, Porta F, Mussa A, et al.(2010) Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. PLoS One 5:e14167
24. Shintaku H, Kure S, Ohura T, et al.(2004) Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr Res 55:425-430
25. Trefz FK, Burton BK, Longo N, et al.(2009) Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 154:700-707
26. Viau KS, Wengreen HJ, Ernst SL, Cantor NL, Furtado LV, Longo N (2011) Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J Inherit Metab Dis 34(4):963-971